Abstract
Breast cancer is the most common cancer among women, and both low-grade inflammation and cathepsins might have important roles in breast cancer. We questioned whether prediagnostic circulating levels of C-reactive protein (CRP), cathepsin B, and cathepsin S were associated with breast cancer risk. Sixty-nine incident breast cancer cases diagnosed after blood collection and 719 controls from the Swedish Mammography Cohort were analyzed for systemic CRP, cathepsin B, and cathepsin S. Cathepsin S and inflammation (high-sensitivity CRP [hsCRP])-adjusted cathepsin S were inversely associated with breast cancer risk (cathepsin S: odds ratio [OR] for top vs. bottom tertile=0.46; 95% confidence interval [CI]=0.23–0.92; p trend=0.02; hsCRP-adjusted cathepsin S: OR of 0.44; 95% CI=0.22–0.87; p trend=0.02). hsCRP was significantly associated with increased breast cancer risk (OR for top vs. bottom tertile=2.01; 95% CI=1.02–3.95; p trend=0.04). No significant association was observed between cathepsin B and breast cancer risk (OR for top vs. bottom tertile=0.67; 95% CI=0.32–1.40; p trend=0.30). These observations lead to the hypothesis that levels of cathepsin S and hsCRP observed in women who later developed breast cancer may provide prognostic information regarding tumor development and need to be evaluated in prospective studies. Antioxid. Redox Signal. 23, 1298–1302.
Get full access to this article
View all access options for this article.
